Journal of Infectious Diseases & Therapy
Open Access

Research Article

Efficacy Testing of Orally Administered Antibiotics against an Inhalational Bacillus anthracis Infection in BALB/C Mice

Graham J Hatch, Simon R Bate, Anthony Crook, Nicola Jones, Simon G Funnell and Julia Vipond*
Public Health England, Porton Down, Salisbury, SP4 0JG, UK
Corresponding Author :	Julia Vipond Public Health England, Porton Down, Salisbury, UK Tel: +4401980 612584 Fax: +44 (0)1980 619894 E-mail:julia.vipond@phe.gov.uk
Received August 15, 2014; Accepted October 16, 2014; Published October 28, 2014
Citation: Hatch GJ, Bate SR, Crook A, Jones N, Funnell SG, et al. (2014) Efficacy Testing of Orally Administered Antibiotics against an Inhalational Bacillus anthracis Infection in BALB/C Mice. J Infect Dis Ther 2:175. doi: 10.4172/2332-0877.1000175
Copyright: © 2014 Hatch GJ, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Related article at Pubmed Scholar Google

Anthrax is a potentially fatal disease in man, and events of the last decade have highlighted the possibility for Bacillus anthracis to be used as a biological weapon through deliberate release. Whilst outbreaks of anthrax occur in several countries, there are only a few areas in which outbreaks of inhalational anthrax occur, so it is not possible to test therapies using conventional clinical trials. To overcome these problems, the FDA published the ‘Animal Rule’ in 2002; a rule designed to permit licensure of drugs and biologics intended to reduce or prevent serious conditions caused by exposure to biological and other agents. Due to limited proven post-exposure prophylaxis after inhalational exposure for use in humans, it is essential to have a robust animal model of disease. In a series of three studies conducted in BALB/c mice, the efficacy of postexposure, orally administered antibiotics in preventing disease following inhalational exposure to B. anthracis was evaluated. Mice treated with either azithromycin or clarithromycin displayed a near identical disease progression to the control, untreated mice; in contrast, those treated with levofloxacin, amoxicillin and co-amoxiclav were generally protected with survival of 97%, 95% and 79%, respectively. The details of the assessments and future direction of these studies are presented.